Plain-English translation of NCT06696183 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing gilteritinib, a medication that targets a specific mutation found in some leukemia cells, when combined with two standard leukemia drugs called venetoclax and azacitidine. The researchers want to find the best dose of the new medication that works safely and effectively alongside these standard treatments. If you have a type of leukemia with a specific genetic mutation and your doctor says you're not a candidate for intensive chemotherapy, this trial may be an option for you.
Many people with newly diagnosed leukemia cannot receive standard intensive chemotherapy because of age, overall health, or other medical conditions. This medication targets a specific genetic change in leukemia cells, and researchers hope that combining it with two established drugs will offer these patients a more effective treatment option.
You likely qualify if…
You likely don't qualify if…
You would take the new medication along with the two standard leukemia drugs over a series of treatment cycles. The trial tests different doses and schedules of the medication combined with different durations of the standard drugs to see what works best. You would visit the trial site regularly for blood tests, exams, and monitoring to track how well the treatment is working and watch for any side effects.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
Germany
Phase
Testing effectiveness
Sponsor
Technische Universität Dresden
Enrollment target
~60 participants
Started
April 2025
Primary completion
April 2029
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Prof. Dr. Christoph Röllig, MD, MSc
Technische Universität Dresden
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.